EA200100304A1 - Способ модуляции эффекторных т-клеток памяти и композиции - Google Patents

Способ модуляции эффекторных т-клеток памяти и композиции

Info

Publication number
EA200100304A1
EA200100304A1 EA200100304A EA200100304A EA200100304A1 EA 200100304 A1 EA200100304 A1 EA 200100304A1 EA 200100304 A EA200100304 A EA 200100304A EA 200100304 A EA200100304 A EA 200100304A EA 200100304 A1 EA200100304 A1 EA 200100304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulation
compositions
cells
effective memory
methods
Prior art date
Application number
EA200100304A
Other languages
English (en)
Other versions
EA005948B1 (ru
Inventor
Даниел Маджилави
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200100304A1 publication Critical patent/EA200100304A1/ru
Publication of EA005948B1 publication Critical patent/EA005948B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Это изобретение относится к способам избирательной модуляции эффекторных T-лимфоцитов памяти у субъекта в случае необходимости. При осуществлении этих способов используют CD2-связывающие агенты.Отчет о международном поиске был опубликован 2000.06.29
EA200100304A 1998-08-31 1999-08-31 Применение cd2-связывающего агента для избирательного снижения числа cd45ro-позитивных эффекторных т-лимфоцитов памяти в организме пациента EA005948B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9845698P 1998-08-31 1998-08-31
PCT/US1999/020026 WO2000012113A2 (en) 1998-08-31 1999-08-31 Method of modulating memory effector t-cells using a cd2-binding agent, and compositions

Publications (2)

Publication Number Publication Date
EA200100304A1 true EA200100304A1 (ru) 2001-10-22
EA005948B1 EA005948B1 (ru) 2005-08-25

Family

ID=22269362

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100304A EA005948B1 (ru) 1998-08-31 1999-08-31 Применение cd2-связывающего агента для избирательного снижения числа cd45ro-позитивных эффекторных т-лимфоцитов памяти в организме пациента

Country Status (26)

Country Link
US (2) US20020009446A1 (ru)
EP (1) EP1109570B1 (ru)
JP (1) JP2002523071A (ru)
KR (1) KR20010085687A (ru)
CN (1) CN100473417C (ru)
AT (1) ATE306932T1 (ru)
AU (1) AU764020B2 (ru)
BR (1) BR9913285A (ru)
CA (1) CA2339299C (ru)
CZ (1) CZ298238B6 (ru)
DE (1) DE69927831T2 (ru)
DK (1) DK1109570T3 (ru)
EA (1) EA005948B1 (ru)
EE (1) EE200100123A (ru)
ES (1) ES2252999T3 (ru)
HK (2) HK1038186A1 (ru)
HU (1) HUP0103563A3 (ru)
IL (2) IL141486A0 (ru)
IS (1) IS5848A (ru)
MX (1) MXPA01002111A (ru)
NO (1) NO20010956L (ru)
NZ (1) NZ510831A (ru)
PL (1) PL346339A1 (ru)
TR (1) TR200100607T2 (ru)
WO (1) WO2000012113A2 (ru)
ZA (1) ZA200101213B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EA005948B1 (ru) * 1998-08-31 2005-08-25 Байоджен, Инк. Применение cd2-связывающего агента для избирательного снижения числа cd45ro-позитивных эффекторных т-лимфоцитов памяти в организме пациента
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CZ20032081A3 (cs) * 2001-02-01 2004-01-14 Biogen, Inc. Kombinace inhibitoru interakce CD2/LFA-3 a UVB záření pro použití při léčení kožních onemocnění
US7858095B2 (en) * 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
CA2555144A1 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
BRPI0510691A (pt) * 2004-05-04 2007-12-26 Genaissance Pharmaceuticals marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
WO2005115436A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PT2021025T (pt) 2006-05-12 2016-11-21 Ith Immune Therapy Holdings Ab Método e meios para tratar doença intestinal inflamatória
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
EA023912B1 (ru) 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
US20230071196A1 (en) * 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
EP0091539B2 (en) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0607353A1 (en) * 1991-10-07 1994-07-27 Biogen, Inc. Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
EA005948B1 (ru) * 1998-08-31 2005-08-25 Байоджен, Инк. Применение cd2-связывающего агента для избирательного снижения числа cd45ro-позитивных эффекторных т-лимфоцитов памяти в организме пациента
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
CZ20032081A3 (cs) * 2001-02-01 2004-01-14 Biogen, Inc. Kombinace inhibitoru interakce CD2/LFA-3 a UVB záření pro použití při léčení kožních onemocnění
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease

Also Published As

Publication number Publication date
IS5848A (is) 2001-02-16
KR20010085687A (ko) 2001-09-07
BR9913285A (pt) 2001-05-15
MXPA01002111A (es) 2003-03-27
US20020009446A1 (en) 2002-01-24
HK1040186A1 (zh) 2002-05-31
EE200100123A (et) 2002-06-17
EP1109570B1 (en) 2005-10-19
DE69927831D1 (de) 2006-03-02
CA2339299C (en) 2009-02-10
ATE306932T1 (de) 2005-11-15
WO2000012113A2 (en) 2000-03-09
NO20010956L (no) 2001-04-30
TR200100607T2 (tr) 2001-06-21
EA005948B1 (ru) 2005-08-25
AU6024499A (en) 2000-03-21
PL346339A1 (en) 2002-02-11
DE69927831T2 (de) 2006-07-20
WO2000012113A3 (en) 2000-06-29
AU764020B2 (en) 2003-08-07
CZ298238B6 (cs) 2007-08-01
EP1109570A2 (en) 2001-06-27
HK1038186A1 (en) 2002-03-08
US20060233796A1 (en) 2006-10-19
ZA200101213B (en) 2002-02-13
NZ510831A (en) 2002-12-20
CN1315866A (zh) 2001-10-03
IL141486A (en) 2007-12-03
JP2002523071A (ja) 2002-07-30
IL141486A0 (en) 2002-03-10
CA2339299A1 (en) 2000-03-09
NO20010956D0 (no) 2001-02-26
CN100473417C (zh) 2009-04-01
DK1109570T3 (da) 2006-03-06
CZ2001725A3 (cs) 2001-08-15
HUP0103563A2 (hu) 2002-01-28
HUP0103563A3 (en) 2004-04-28
ES2252999T3 (es) 2006-05-16

Similar Documents

Publication Publication Date Title
EA200100304A1 (ru) Способ модуляции эффекторных т-клеток памяти и композиции
RS49685B (sr) Novi oblik jedinjenja
NO990760D0 (no) 1,4-heterocykliske metallproteaseinhibitorer
DE69708120T2 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
BR9808491A (pt) Compostos calcilìticos
DE69716934T2 (de) 1,3-diheterozyklische metalloprotease inhibitoren
DE69716404D1 (de) Zusammensetzungen auf basis von nonafluormethoxybutan
ES2191830T3 (es) Inhibidores de trombina.
DE59709255D1 (de) Kühlbare Schaufel
DE69423233T2 (de) Amphoterestensid und parfümenthaltende, flüssige waschmittelzusammensetzungen für harte oberflächen
ID16104A (id) Inhibitor-inhibitor serin protease.
DE69721244D1 (de) Kühlvorrichtung
DE69727711D1 (de) N-alkyl-ammonium-acetonitril-salze, methoden dazu und zusammensetzungen die diese enthalten
PT71983B (en) N-aryl-n'-imidazol-2-ylureas compositions and methods
DK1012186T3 (da) Keratinocyt-vækstfaktorer og anvendelser deraf
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
BG103017A (en) Liquid crystal compositions
EA199900534A1 (ru) Имидазопиридазины
IL139604A (en) Fibrinogen-beta chain derived peptide, compositions comprising same and use thereof
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
EA200000403A1 (ru) Новые соединения, полезные в качестве нейропротекторов
DE69713618D1 (de) Pfropfcopolymerisierte zusammensetzungen
AU1730797A (en) 3-substituted-4-oxa-1-azabicyclo{3,2,0}heptan-7-one as cysteine protease inhibitors
DE69719050T2 (de) Enzymhaltige zusammensetzungen
DE9315248U1 (de) Verschleißklammer zur Wiederverschließung von Tüten

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU